Showing results 1 to 1 of 1
Title | Author(s) | Issue Date | |
---|---|---|---|
MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia Journal:Clinical Lymphoma, Myeloma and Leukemia | 1-Sep-2023 |